title: Neoadjuvant chemotherapy for Ewing's tumour of bone: recent experience at the Rizzoli Orthopaedic Institute.
abstract: The results achieved in 157 patients with non-metastatic Ewing's sarcoma of the bone treated at a single institution between 1991 and 1997 according to a new protocol (REN-3) are reported. Induction chemotherapy consisted of two cycles of 'VAC': vincristine (V), doxorubicin (A), cyclophosphamide (C) alternated with one cycle of 'VIAc': V, ifosfamide (I), actinomycin (Ac). After local treatment, patients received three more cycles of VAC, two of VIAc, three cycles of I plus etoposide (E) and two cycles with V, C and Ac. Local treatment was surgery in 53% of patients, surgery+radiotherapy in 25% and radiotherapy only in 22%. With a follow-up ranging between 4 and 10 years (mean: 7 years), 110 patients (70%) remained continuously event-free, 2 patients died of toxicity and 45 patients relapsed: 33 due to metastases and 12 due to local recurrence always associated with metastases. The 5-year event-free survival (EFS) and overall survival (OS) were 71.0 and 76.5% respectively. These results are significantly better that the ones achieved in our previous three studies in which a three-drug VAC regimen (REA-1), and 4-drug VACAc regimen (REA-2 and REN-1) was used, and in our most recent study (REN-2) which was based on a six-drug regimen as in the present study, but where I and Ac were used only after the local treatment. However, since REN-3 surgery was used in a significantly larger number of patients, we cannot say whether the better outcome of this study was due to the use of a six-drug regimen with an early delivery of ifosfamide and actinomycin, or to the wider use of surgery as local treatment or both.
authors.affiliation: Section of Chemotherapy, Rizzoli Orthopaedic Institute, Bologna, Italy. gaetano.bacci@ior.it
authors.forename: G
authors.initials: G
authors.lastname: Bacci
authors.forename: M
authors.initials: M
authors.lastname: Mercuri
authors.forename: A
authors.initials: A
authors.lastname: Longhi
authors.forename: F
authors.initials: F
authors.lastname: Bertoni
authors.forename: E
authors.initials: E
authors.lastname: Barbieri
authors.forename: D
authors.initials: D
authors.lastname: Donati
authors.forename: S
authors.initials: S
authors.lastname: Giacomini
authors.forename: P
authors.initials: P
authors.lastname: Bacchini
authors.forename: E
authors.initials: E
authors.lastname: Pignotti
authors.forename: C
authors.initials: C
authors.lastname: Forni
authors.forename: S
authors.initials: S
authors.lastname: Ferrari
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D020360:Neoadjuvant Therapy / Q000379:methods; D009364:Neoplasm Recurrence, Local / Q000209:etiology; D010349:Patient Compliance; D000091402:Prohibitins; D012512:Sarcoma, Ewing / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery